CBM BioPharma, Inc

CBM BioPharma, Inc (cbmbiopharmainc.com) is a privately held pharmaceutical company with exclusive drug development rights from world renowned partners like Wake Forest University and University of Texas. The Company has a team of leading drug development scientists who help advance their technology. The CBM BioPharma, Inc platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and pancreatic cancer.



Two specific proprietary drugs that are currently being researched are:

KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)

Developed at Wake Forest School of Medicine, AML and ALL drug, KPC34, is a next generation treatment designed to overcome multiple resistance challenges observed with the current standard of care. KPC34 has also been shown to be more effective in AML relapse cases, notably increasing the lifespan of mice treated with the drug. One competitive benefit of KPC34 includes its ability to be orally administered. This is critical for patients that are unable to tolerate repeated cycles of chemotherapy. In addition, it has served to double the mean survival time versus the current standard of care treatments in a mouse model of leukemia.

DHA-dFdC (Pancreatic Cancer Drug)

Developed at the University of Texas at Austin, DHA-dFdC has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models. DHA-dFdC also overcomes tumor cell resistance to current chemotherapeutic drugs. Pancreatic cancer is a deadly disease that affects millions of people around the world.

Video

A significant number of acute lymphoblastic leukemia (ALL) patients will suffer from central nervous system involvement of their leukemia. This mouse model of ALL spreads to the central nervous system of mice causing hind limb paralysis. Repeated treatment with KPC34 showed an improvement of this in several test animals treated at Wake Forest. This video demonstrates one such test subject. These results demonstrate the potential of KPC34 to treat leukemia that has spread to the nervous system.



Published Papers

KPC-34

Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms

Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer

Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation

Short Summary of KPC34

The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia

Wake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancer


DHA-dFdC

Short-term Toxicity Study of DHA-dFdC

Study of DHA-dFdC

Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside